Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ONCE
Delisted

Spark Therapeutics Stock Price (Quote)

$113.57
+0 (+0%)
At Close: Jan 24, 2020

Range Low Price High Price Comment
30 days $113.57 $113.57 Friday, 24th Jan 2020 ONCE stock ended at $113.57. During the day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57.
90 days $108.00 $113.90
52 weeks $40.64 $114.20

Historical Spark Therapeutics prices

Date Open High Low Close Volume
Jun 20, 2019 $103.75 $104.00 $102.26 $103.01 424 162
Jun 19, 2019 $101.99 $103.50 $101.30 $103.22 524 248
Jun 18, 2019 $99.00 $102.17 $98.21 $101.95 979 557
Jun 17, 2019 $98.00 $99.89 $97.50 $99.69 550 863
Jun 14, 2019 $99.00 $99.18 $96.99 $97.70 719 736
Jun 13, 2019 $100.42 $100.79 $99.09 $99.53 303 797
Jun 12, 2019 $100.07 $101.17 $99.60 $100.13 555 412
Jun 11, 2019 $100.25 $100.50 $99.01 $99.98 738 574
Jun 10, 2019 $97.90 $102.38 $97.35 $100.21 3 430 946
Jun 07, 2019 $108.44 $109.68 $108.02 $109.35 409 504
Jun 06, 2019 $108.60 $108.61 $106.99 $107.94 691 793
Jun 05, 2019 $110.50 $110.62 $108.28 $108.62 732 493
Jun 04, 2019 $109.47 $110.40 $108.67 $110.20 781 943
Jun 03, 2019 $109.26 $109.87 $108.86 $109.01 358 313
May 31, 2019 $109.95 $110.30 $108.87 $109.00 496 489
May 30, 2019 $111.21 $111.21 $110.44 $110.50 137 245
May 29, 2019 $110.91 $111.21 $109.65 $110.93 449 819
May 28, 2019 $110.17 $111.53 $110.17 $111.13 404 588
May 24, 2019 $109.00 $111.73 $108.77 $110.33 508 297
May 23, 2019 $107.70 $108.98 $107.66 $108.84 322 405
May 22, 2019 $108.72 $109.10 $107.85 $108.06 301 069
May 21, 2019 $108.08 $109.19 $107.80 $109.05 274 440
May 20, 2019 $106.87 $108.05 $106.65 $107.66 343 561
May 17, 2019 $108.50 $108.98 $107.63 $107.64 342 224
May 16, 2019 $108.70 $109.07 $108.42 $108.46 238 596
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT